Evira: digital support added to obesity medication for teens
Official title: Evaluation of a Digital Treatment Tool in Combination With Obesity Medications
Run by Karolinska Institutet · NCT06836284 · Data updated 2026-11-12
This study will try adding the Evira digital tool to obesity medication for 12–17-year-olds to see if it improves weight outcomes and sticking with treatment compared with medication alone.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 12 Years to 17 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Karolinska Institutet Academic / other |
| Locations | 3 sites (Linköping and 2 other locations) |
| Status | Recruiting |
| Started | February 13, 2026 |
| Main results expected | April 1, 2027 |
| Study ends | May 1, 2027 |
| Registry record updated | September 10, 2026 |
| Trial ID | NCT06836284 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adolescents aged 12–17 who are being offered liraglutide or semaglutide at participating clinics and whose families agree to join the study are the intended candidates.
✕Probably not a fit
Patients with endocrine disorders beyond well-controlled hypothyroidism, recent or active eating disorders, severe neuropsychiatric conditions affecting adherence, hypothalamic or monogenic obesity, certain genetic syndromes, or other conditions making participation inappropriate may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, two-arm multicenter trial in which adolescents aged 12–17 receiving liraglutide or semaglutide are assigned to medication alone or medication plus the Evira digi-physical tool. Evira combines a home measuring device (that hides raw numbers) with a mobile app that shows BMI SDS trends as a moving average and an individualized target curve, plus continuous communication between families and clinicians. Participants will take part for six months with regular monitoring of weight trajectories and adherence. The study aims to determine whether close home monitoring and digital support improve short-term treatment response and engagement compared with medication alone.
Why it matters
Potential benefit: If successful, adding Evira to medication could help adolescents achieve better weight change and stay engaged with treatment for longer.
How similar studies have gone: Previous trials of liraglutide and semaglutide in 12–17-year-olds showed meaningful short-term BMI SDS reductions but weight often returns after stopping medication, while digital adjuncts are promising but less extensively tested in adolescents.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients offered liraglutide or semaglutide in accordance with the clinic's routines. * Aged 12-17 years at the time of inclusion. * The family agrees to participate in a clinical study. Exclusion Criteria: * Endocrine disorders other than well-controlled hypothyroidism. * Severe neuropsychiatric disorders that may affect adherence to the study. * Eating disorder requiring treatment within the last six months before inclusion or observed during screening prior to inclusion. * Somatic conditions that may complicate the evaluation of treatment outcomes, such as patients on irregular oral corticosteroid treatment. * Hypothalamic or monogenic obesity, and genetic syndromes such as Down syndrome. * Patients deemed unsuitable for participation by the responsible physician.
Where it's running
-
HKH Crown Princess Victoria's Childrens and youth Hospital Linköping
Linköping, Sweden Recruiting -
Länsverksamhet Barn- och ungdomsmedicin Sollefteå
Sollefteå, Sweden Recruiting -
Ystad lasarett, Barn och ungdomsmedicinmottagningen
Ystad, Sweden Recruiting
Study contacts
- Study coordinator: Pernilla Danielsson Liljeqvist, Associate Professor
- Email: pernilla.danielsson.liljeqvist@ki.se
- Phone: 070-837 7734
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Progressive Neuromuscular Stabilization vs. Aerobic Exercise for Obesity in Children
This study tests whether technology-assisted progressive neuromuscular stabilization exercises can improve body composition and balance in children with obesity, compared with standard aerobic exercise.
-
Impact of Food Help on Adherence to Cancer Treatment
This study tests whether providing food assistance helps adults with cancer who have food insecurity stick to their treatment plans.
-
mHealth tool to boost hormone therapy adherence for Latina breast cancer patients
A bilingual, culturally tailored smartphone app plus patient navigation is tested to help Latina women on hormone therapy take their medication as prescribed.
-
MRI study to see how obesity treatments affect body and organ fat in severely obese kids
This study tests whether adding a GLP-1 receptor agonist to lifestyle changes helps improve body composition and organ fat in adolescents with severe obesity.
-
Bottle flow-rate test for babies and feeding patterns
This study tests whether different bottle nipple flow rates affect how much milk a 4–6 month old infant drinks, how they feed, and their sleep, by watching 220 mother–infant pairs.
-
Telenursing to detect and manage side effects from CDK4/6 inhibitors in breast cancer
This project tests whether scheduled phone or video contacts from trained nurses, added to usual care, help people with breast cancer taking CDK4/6 inhibitors notice and manage side effects earlier and stay on treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.